$GBLX
GB SCIENCES INC Stock $gblx

$gblx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000143774924028160 Filed on August 30, 2024

Income Statement

Concept	2024 Q3	2024 Q1	2024
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change
Gross Profit	$0.00	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development			$261.6K
YoY Change			-46.65%
% of Gross Profit
Depreciation & Amortization		$0.00	$620.00
YoY Change			-98.99%
% of Gross Profit
Operating Expenses		$369.9K	$1.421M
YoY Change		-30.16%	-15.06%
Operating Profit	-$157.8K	-$369.9K	-$1.421M
YoY Change	-71.39%	-30.16%	-15.06%
Interest Expense		-$97.16K	-$219.0K
YoY Change		58.27%	22.57%
% of Operating Profit
Other Income/Expense, Net	-$32.74K	$0.00	$58.83K
YoY Change	-127.92%	-100.0%	-41.17%
Pretax Income	-$190.5K	-$467.1K	-$1.362M
YoY Change	-56.12%	-83.7%	-66.99%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$190.5K	-$476.1K	-$1.362M
YoY Change	-56.12%	-83.38%	-66.99%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share		$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	407.1M	406.1M	396.7M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q1	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments		$11.99K	$11.99K
YoY Change		-89.09%	-89.09%
Cash & Equivalents	$2.320K	$11.99K	$11.99K
Short-Term Investments
Other Short-Term Assets		$91.45K	$91.45K
YoY Change		-54.18%	-54.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$93.77K	$103.4K	$103.4K
YoY Change	-59.96%	-66.58%	-66.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$93.77K	$103.4K	$103.4K
Total Long-Term Assets		$0.00	$0.00
Total Assets		$103.4K	$103.4K
YoY Change		-70.64%	-70.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$2.140M	$2.140M
YoY Change		7.95%	7.95%
Accrued Expenses	$112.5K	$0.00	$457.1K
YoY Change	48.75%	-100.0%	8.2%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due		$1.437M	$1.437M
YoY Change		2.95%	2.95%
Total Short-Term Liabilities	$5.441M	$5.096M	$5.096M
YoY Change	12.14%	7.06%	7.06%
LONG-TERM LIABILITIES
Long-Term Debt		$322.0K	$322.0K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$322.0K	$322.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.441M	$5.096M	$5.096M
Total Long-Term Liabilities		$322.0K	$322.0K
Total Liabilities	$5.873M	$5.418M	$5.418M
YoY Change	19.2%	13.82%	13.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.5M	-$110.1M
YoY Change	1.03%	1.25%
Common Stock	$40.82K	$40.72K
YoY Change	1.07%	6.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.780M	-$5.314M	-$5.314M
YoY Change
Total Liabilities & Shareholders Equity	$93.77K	$103.4K	$103.4K
YoY Change	-59.96%	-70.64%	-70.64%

Cashflow Statement

Concept	2024 Q3	2024 Q1	2024
OPERATING ACTIVITIES
Net Income	-$190.5K	-$476.1K	-$1.362M
YoY Change	-56.12%	-83.38%	-66.99%
Depreciation, Depletion And Amortization		$0.00	$620.00
YoY Change			-98.99%
Cash From Operating Activities		-$252.5K	-$975.7K
YoY Change		14.82%	-36.1%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$320.0K
YoY Change
Cash From Investing Activities		$0.00	$320.0K
YoY Change			-1111.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		247.0K	$557.8K
YoY Change		342.97%	-61.12%
NET CHANGE
Cash From Operating Activities		-252.5K	-$975.7K
Cash From Investing Activities		0.000	$320.0K
Cash From Financing Activities		247.0K	$557.8K
Net Change In Cash		-5.470K	-$97.92K
YoY Change		-96.67%	-21.02%
FREE CASH FLOW
Cash From Operating Activities		-$252.5K	-$975.7K
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$252.5K	-$975.7K
YoY Change		14.82%	-37.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	406071028
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	406071028
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	381872561
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	381872561
CY2024	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	000-55462
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3733133
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	9205 W. Russell Road, Suite 240
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89148
CY2024	dei	City Area Code CityAreaCode	866
CY2024	dei	Local Phone Number LocalPhoneNumber	721-0297
CY2024	dei	Security12g Title Security12gTitle	Common Stock $.0001 Par Value
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	4000000	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	407071028
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11991	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109912	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	91451	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	199592	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	103442	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	309504	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	42819	usd
CY2024Q1	us-gaap	Assets Assets	103442	usd
CY2023Q1	us-gaap	Assets Assets	352323	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	457093	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	346806	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	0	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	75628	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1437307	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1396077	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1060825	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	958455	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5095557	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4759706	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	322000	usd
CY2023Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2024Q1	us-gaap	Liabilities Liabilities	5417557	usd
CY2023Q1	us-gaap	Liabilities Liabilities	4759706	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	40721	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	38187	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104712156	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104259745	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110066992	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108705315	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5314115	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4407383	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103442	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	352323	usd
CY2024	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2024	us-gaap	Gross Profit GrossProfit	0	usd
CY2023	us-gaap	Gross Profit GrossProfit	0	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	1420509	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1672281	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-1420509	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1672281	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	218973	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	178652	usd
CY2024	gblx	Gain Loss On Impairment Of Capitalized Patent Costs GainLossOnImpairmentOfCapitalizedPatentCosts	-42195	usd
CY2023	gblx	Gain Loss On Impairment Of Capitalized Patent Costs GainLossOnImpairmentOfCapitalizedPatentCosts	-2374261	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	320000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	100000	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	58832	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2452913	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1361677	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4125194	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-1361677	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4125194	usd
CY2024	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	278315	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-0	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1639992	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4125194	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	396728680
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	357721189
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1782872	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17333	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1483350	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4125194	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4407383	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	219168	usd
CY2024	gblx	Exercise Of Warrants For Stock Value ExerciseOfWarrantsForStockValue	253529	usd
CY2024	gblx	Adjustments To Additional Paid In Capital Brokerage Fees On Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalBrokerageFeesOnExerciseOfWarrants	-17752	usd
CY2024	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	0	usd
CY2024	gblx	Adjustments To Additional Paid In Capital Warrant Reinstatement And Repricing AdjustmentsToAdditionalPaidInCapitalWarrantReinstatementAndRepricing	278315	usd
CY2024	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	278315	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-1361677	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5314115	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-1361677	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-4125194	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	624	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	61660	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	219168	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	17333	usd
CY2024	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-320000	usd
CY2023	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
CY2024	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	41230	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	60024	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	42195	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2374261	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-108140	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	105659	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	157593	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-20195	usd
CY2024	gblx	Increase Decrease In Accrued Liabilities Excluding Interest Payable IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable	-75628	usd
CY2023	gblx	Increase Decrease In Accrued Liabilities Excluding Interest Payable IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable	66001	usd
CY2024	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	110287	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-37963	usd
CY2024	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	102370	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	61960	usd
CY2024	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	0	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	120911	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-975698	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1526861	usd
CY2024	us-gaap	Proceeds From Recoveries Of Loan Previously Charged Off ProceedsFromRecoveriesOfLoanPreviouslyChargedOff	320000	usd
CY2023	us-gaap	Proceeds From Recoveries Of Loan Previously Charged Off ProceedsFromRecoveriesOfLoanPreviouslyChargedOff	0	usd
CY2024	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	31650	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	320000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31650	usd
CY2024	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	235777	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2024	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	322000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1483350	usd
CY2024	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	48820	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	557777	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1434530	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-97921	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-123981	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	109912	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	233893	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11991	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	109912	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2024	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2024	gblx	Noncash Additions For Capitalized Patent Costs NoncashAdditionsForCapitalizedPatentCosts	7700	usd
CY2023	gblx	Noncash Additions For Capitalized Patent Costs NoncashAdditionsForCapitalizedPatentCosts	246132	usd
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110066992	usd
CY2024Q1	gblx	Working Capital Deficit WorkingCapitalDeficit	-4992115	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-975698	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectability of notes receivable, valuation of initial right-of-use assets and corresponding lease liabilities, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are <em style="font: inherit;">not</em> readily apparent from other sources. The actual results the Company experiences <em style="font: inherit;"> may </em>differ materially and adversely from these estimates.</p> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	261550	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	490291	usd
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	173992145
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	167252135
CY2024Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1759307	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	-0	usd
CY2024Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1759307	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	1060825	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	375964	usd
CY2024Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	52148929	usd
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	52661859	usd
CY2024Q1	gblx	Operating Loss Carryforwards Subject To Expiration OperatingLossCarryforwardsSubjectToExpiration	34481122	usd
CY2024Q1	gblx	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	18180737	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-194971	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-182405	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	8508	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	9246	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	430270	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-756430	usd
CY2024	gblx	Effective Income Tax Rate Reconciliation Adjustments To Valuation Of Deferred Tax Assets EffectiveIncomeTaxRateReconciliationAdjustmentsToValuationOfDeferredTaxAssets	-243807	usd
CY2023	gblx	Effective Income Tax Rate Reconciliation Adjustments To Valuation Of Deferred Tax Assets EffectiveIncomeTaxRateReconciliationAdjustmentsToValuationOfDeferredTaxAssets	929589	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	102370	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	61960	usd
CY2024	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	102370	usd
CY2023	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	61960	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3191824	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3147724	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11058990	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10934127	usd
CY2024Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	635250	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	-0	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1369	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	175067	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	209714	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14075747	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14506018	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14075747	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14506018	usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	221650	usd
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	75124673
CY2023	gblx	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	56835004
CY2023	gblx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	0.1
CY2023	gblx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
CY2023	gblx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
CY2023	gblx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	9201000
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	122758677
CY2024	gblx	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	23006492
CY2024	gblx	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	0.01
CY2024	gblx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	25348467
CY2024	gblx	Class Of Warrant Or Right Exercised During Period Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice	0.01
CY2024	gblx	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	38337538
CY2024	gblx	Class Of Warrant Or Right Cancelled During Period Exercise Price ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice	0
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	82079164
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	23000000
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.01
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	219168	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	219168	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17333	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2024	dei	Auditor Name AuditorName	Assurance Dimensions, Inc.
CY2024	dei	Auditor Location AuditorLocation	Coral Springs, FL
CY2024	dei	Auditor Firm AuditorFirmId	5036

Files In Submission

Name	View Source	Status
0001437749-24-028160-index-headers.html	Edgar Link	pending
0001437749-24-028160-index.html	Edgar Link	pending
0001437749-24-028160.txt	Edgar Link	pending
0001437749-24-028160-xbrl.zip	Edgar Link	pending
a01.jpg	Edgar Link	pending
a02.jpg	Edgar Link	pending
exa01.jpg	Edgar Link	pending
ex_717913.htm	Edgar Link	pending
ex_717914.htm	Edgar Link	pending
ex_717915.htm	Edgar Link	pending
ex_717916.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gblx-20240331.xsd	Edgar Link	pending
gblx20240331_10k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gblx-20240331_cal.xml	Edgar Link	unprocessable
gblx-20240331_lab.xml	Edgar Link	unprocessable
gblx-20240331_def.xml	Edgar Link	unprocessable
gblx-20240331_pre.xml	Edgar Link	unprocessable
gblx20240331_10k_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GBLX
GB SCIENCES INC Stock $gblx

2024 Q3 Form 10-K Financial Statement

#000143774924028160 Filed on August 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GBLX GB SCIENCES INC Stock $gblx

2024 Q3 Form 10-K Financial Statement

#000143774924028160 Filed on August 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GBLX
GB SCIENCES INC Stock $gblx